Guidelines on hepatitis B and C testing (2017) Geneva: World Health Organization; (http://apps.who.int/iris/bitstream/10665/254621/1/9789241549981, accessed 17 July 2018).

Bowen DG, Walker CM (2005) Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436(7053):946–952. https://doi.org/10.1038/nature04079

Article  CAS  PubMed  Google Scholar 

McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339(21):1485–1492. https://doi.org/10.1056/NEJM199811193392101

Article  CAS  PubMed  Google Scholar 

Christoph Sarrazin C, Hézode S, Zeuzem J-M, Pawlotsky (2012) Antiviral strategies in hepatitis C virus infection. J Hepatol 56 (Suppl 188–100. https://doi.org/10.1016/S0168-8278(12)60010-5

Welsch C, Jesudian A, Zeuzem S, Jacobson I (2012) New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 61(Suppl 1):i36–46. https://doi.org/10.1136/gutjnl-2012-302144

Article  CAS  PubMed  Google Scholar 

Micallef JM, Kaldor JM, Dore GJ (2006) Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 13:34–41. https://doi.org/10.1111/j.1365-2893.2005.00651.x

Article  CAS  PubMed  Google Scholar 

Kuiken C, Simmonds P (2009) Nomenclature and numbering of the hepatitis C virus. Methods Mol Biol 510:33–53. https://doi.org/10.1007/978-1-59745-394-3_4

Article  CAS  PubMed  Google Scholar 

Weisser NE, Hall JC (2009) Applications of single-chain variable fragment antibodies in therapeutics and diagnostics. Biotechnol Adv 27:502–520. https://doi.org/10.1016/j.biotechadv.2009.04.004

Article  CAS  PubMed  Google Scholar 

Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M (2012) 2012 scFv Antibody: Principles and Clinical Application. J Immunol Res vol Article ID 980250:15. https://doi.org/10.1155/2012/980250

Article  CAS  Google Scholar 

Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Whitlow M; (1988) Single-chain antigen-binding proteins. Science 242:423–426. https://doi.org/10.1126/science.3140379

Article  CAS  PubMed  Google Scholar 

Sapats SI, Heine HG, Trinidad L, Gould GJ, Foord AJ, Doolan SG, Prowse S, Ignjatovic J (2003) Generation of chicken single chain antibody variable fragments (scFv) that differentiate and neutralize infectious bursal disease virus (IBDV). Arch Virol 148:497–515. https://doi.org/10.1007/s00705-002-0931-2

Article  CAS  PubMed  Google Scholar 

Li T-W, Cheng S-F, Tseng Y-T, Yang Y-C, Liu W-C, Wang S-C, Chou M-J, Lin Y-J, Wang Y, Hsiao P-W, Wu S-C Ding-Kwo Chang 2016 Development of single-chain variable fragments (scFv) against influenza virus targeting hemagglutinin subunit 2 (HA2). Arch Virol, 161, 19–31. https://doi.org/10.1007/s00705-015-2625-6

Li B, Ye J, Lin Y, Wang M, Jia R (2014) Jianguo ZhuSelection and characterization of single-chain recombinant antibodies against phosphoprotein of Newcastle disease virus. Biologicals, 42, 285–289. https://doi.org/10.1016/j.biologicals.2014.05.006

Das S, Mullick R, Kumar A, Tandon H, Bose M, Gouthamchandra K, Chandra M, Ravishankar B, Khaja MN, Srinivasan N, Das S, Shaila MS, Karande AA 2017 Identification of a novel epitope in the C-terminus of HCV-E2 protein that induces potent and cross-reactive neutralizing antibodies. J Gen Virol. 98(5): 962–976. https://doi.org/10.1099/jgv.0.000735

Das S, Shetty RK, Kumar A, Shridharan RN, Tatineni R, Chi G, Mukherjee A, Das S, Subbarao SM, Karande AA 2013 Monoclonal Antibodies against Hepatitis C Genotype 3a Virus Like Particle Inhibit Virus Entry in Cell Culture System. PLoS ONE, 8:e53619 https://doi.org/10.1371/journal.pone.0053619

Kanyarat Thueng-in Jeeraphong Thanongsaksrikul, Surasak Jittavisutthikul, Watee Seesuay, Monrat Chulanetra, Yuwaporn Sakolvaree, Potjanee Srimanote, Wanpen Chaicumpa 2014 Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase, mAbs, 6:5, 1327–1339 https://doi.org/10.4161/mabs.29978

Kumar A, Das S, Mullick R, Lahiri P, Tatineni R, Goswami D, Bhat P, Torresi J, Gowans EJ, Karande AA, Das S 2016 Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: A novel VLP prime-adenovirus boost strategy. Vaccine 34(8):1115–1125 https://doi.org/10.1016/j.vaccine.2015.11.061

Reddy U, Mullick R, Kumar A, Sharma G, Bag P, Laha Roy C, Sudha G, Tandon H, Dave P, Shukla A, Srinivasan P, Nandhitha M, Srinivasan, Das S 2018 A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage. Antiviral Res 150: 47–59. https://doi.org/10.1016/j.antiviral.2017.12.004

Kabat; T EA, Wu T (1991) Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J Immunol 147(5):1709–1719. https://doi.org/10.4049/jimmunol.147.5.1709

Article  Google Scholar